Brittany B Dennis
Biographic Data
| ID | 5476240 |
|---|---|
| NAME | Brittany B Dennis |
| GIVEN NAMES | Brittany B |
| FAMILY NAME | Dennis |
| SIGNATURE | DENNIS B B |
| AFFILIATIONS | McMaster University |
| ORCID | 0000-0002-3691-5400 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2013 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Cannabis use and opioid relapse
Our analysis failed to show cannabis to be protective against relapse to opioid use in patients receiving buprenorphine-naloxone for OUD. We identified that individuals who inject drugs, are on higher doses of buprenorphine-naloxone, or have been in treatment for less than two years have a higher hazard for relapse. The presence of such factors may thus warrant closer patient follow-up and more stringent treatment protocols to mitigate risk of re…
A tutorial on sensitivity analyses in clinical trials
BACKGROUND: Sensitivity analyses play a crucial role in assessing the robustness of the findings or conclusions based on primary analyses of data in clinical trials. They are a critical way to assess the impact, effect or influence of key assumptions or variations--such as different methods of analysis, definitions of outcomes, protocol deviations, missing data, and outliers--on the overall conclusions of a study.The current paper is the second i…
No prominent works on this page.
A tutorial on sensitivity analyses in clinical trials
BACKGROUND: Sensitivity analyses play a crucial role in assessing the robustness of the findings or conclusions based on primary analyses of data in clinical trials. They are a critical way to assess the impact, effect or influence of key assumptions or variations--such as different methods of analysis, definitions of outcomes, protocol deviations, missing data, and outliers--on the overall conclusions of a study.The current paper is the second i…
Cannabis use and opioid relapse
Our analysis failed to show cannabis to be protective against relapse to opioid use in patients receiving buprenorphine-naloxone for OUD. We identified that individuals who inject drugs, are on higher doses of buprenorphine-naloxone, or have been in treatment for less than two years have a higher hazard for relapse. The presence of such factors may thus warrant closer patient follow-up and more stringent treatment protocols to mitigate risk of re…
Data science (2 works) · Medicine (2 works) · Alternative medicine (1 work) · Artificial Intelligence (1 work) · Cannabis (1 work) · Cannabis and Cannabinoid Research (1 work) · Clinical trial (1 work) · Computer Science (1 work) · Data mining (1 work) · Exploratory analysis (1 work)